Mabqi is committed to delivering highly developable and functional human antibodies-based leads in various therapeutic applications and areas such as oncology, autoimmune and inflammatory diseases, …
Our tailored and integrated solution is designed to:
Our team has demonstrated its commitment to excellence and collaboration through dozens of antibody discovery programs.
Unlock a new era in biotherapeutics with an antibody discovery studio—purpose-built platforms streamlining every step from target to validated candidate.
Our approach enables in vitro selection of robust and stable antibodies that bind to target antigen with high specificity. This approach is suited for virtually any targets including ion channels, GPCRs, peptides, proteins, peptide-MHC complexes,… It works effectively regardless of the antigen’s form or environment, whether it’s a protein, cell, or peptide.
Our versatile platform excels in addressing complex programs by seamlessly integrating multiple requirements. This adaptability allows us to tackle a wide array of specifications, including:
For each target of interest, we perform customized antibody screening programs using our libraries of synthetic human antibodies (HuscI2TM, pHuscI2TM) and highly innovative, flexible and robust processes.
Our expert team provides comprehensive solutions for antibody discovery and development programs, delivering seamless support across the entire discovery workflow.
1. Optimal antibody selection strategies:
Bio-panning strategies are performed on proteins, peptides, cells, liposomes, VLPs, …
The combination of phage and yeast display takes advantage of both platforms by starting with a vast number of antibodies in the phage display selections followed by yeast display to refine and select a diverse population of high-affinity binders (cross-reactivity, additional specificity or requested characteristics).
2. Comprehensive antibody hits’ characterization:
Comprehensive binding affinity evaluation for soluble and membrane-bound targets, EC50 binding potency assessment, cell-based flow cytometry assay to determine the binding potency based on cell line expression, epitope specificity, cross-reactivity, …
3. Rigorous functional validation processes: internalization assays, direct cytotoxicity assays, ….
Further reformatting to IgG, BsAb, ADC formats can be performed with additional in-depth profiling of antibodies.
Our antibody discovery platform delivers fully human antibody unique hits with :
Together, let’s innovate to improve lives and advance human health!
For questions about our pipeline, accessing our platform technologies, leveraging our discovery programs, or discussing strategic partnerships, please contact us.
